Adaptive Biotechnologies (ADPT) Enterprise Value (2018 - 2026)

Adaptive Biotechnologies has reported Enterprise Value for 9 years, with the latest figure at -$210.4 million in Q1 2026.

• Quarterly Enterprise Value fell 8.68% year-over-year to -$210.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$210.4 million (down 8.68% YoY) and the FY2025 annual result came in at -$220.8 million, up 0.78% from the prior year.
• Enterprise Value rose to -$210.4 million in Q1 2026 per ADPT's latest filing, from -$220.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$193.6 million in Q1 2025 and troughed at -$508.1 million in Q3 2022.
• A 5-year average of -$319.6 million and a median of -$309.0 million in 2024 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 49.1% in 2022, down 41.17% in 2022.
• Over 5 years, Enterprise Value stood at -$498.3 million in 2022, then surged by 30.45% to -$346.5 million in 2023, then surged by 35.79% to -$222.5 million in 2024, then grew by 0.78% to -$220.8 million in 2025, then gained by 4.68% to -$210.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$210.4 million, -$220.8 million, and -$213.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.